AU2001260140A1 - Nematodes as model organisms for the investigation of neurodegenerative diseases, in particular parkinsons disease, uses and methods for the discovery of substances and genes which can be used in the treatment of the above disease states and identification of a nematode gene. - Google Patents

Nematodes as model organisms for the investigation of neurodegenerative diseases, in particular parkinsons disease, uses and methods for the discovery of substances and genes which can be used in the treatment of the above disease states and identification of a nematode gene.

Info

Publication number
AU2001260140A1
AU2001260140A1 AU2001260140A AU6014001A AU2001260140A1 AU 2001260140 A1 AU2001260140 A1 AU 2001260140A1 AU 2001260140 A AU2001260140 A AU 2001260140A AU 6014001 A AU6014001 A AU 6014001A AU 2001260140 A1 AU2001260140 A1 AU 2001260140A1
Authority
AU
Australia
Prior art keywords
nematodes
investigation
genes
discovery
substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001260140A
Other languages
English (en)
Inventor
Ralf Baumeister
Giuseppe Cassata
Marius Honer
Wolfgang Link
Karlheinz Tovar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avntis Pharma Deutschland GmbH
Original Assignee
ELEGENE AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ELEGENE AG filed Critical ELEGENE AG
Publication of AU2001260140A1 publication Critical patent/AU2001260140A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
    • A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
    • A01K67/0335—Genetically modified worms
    • A01K67/0336—Genetically modified Nematodes, e.g. Caenorhabditis elegans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C07K14/43545—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Animal Husbandry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2001260140A 2000-03-22 2001-03-21 Nematodes as model organisms for the investigation of neurodegenerative diseases, in particular parkinsons disease, uses and methods for the discovery of substances and genes which can be used in the treatment of the above disease states and identification of a nematode gene. Abandoned AU2001260140A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10014109 2000-03-22
DE10014109 2000-03-22
PCT/EP2001/003214 WO2001070944A2 (fr) 2000-03-22 2001-03-21 Nematodes utilises comme organismes modeles servant a etudier des maladies neurodegeneratives, notamment la maladie de parkinson, et procede pour deceler des substances et des genes qui peuvent etre utilises pour le traitement de ces maladies, et identification d'un gene de nematode.

Publications (1)

Publication Number Publication Date
AU2001260140A1 true AU2001260140A1 (en) 2001-10-03

Family

ID=7635837

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001260140A Abandoned AU2001260140A1 (en) 2000-03-22 2001-03-21 Nematodes as model organisms for the investigation of neurodegenerative diseases, in particular parkinsons disease, uses and methods for the discovery of substances and genes which can be used in the treatment of the above disease states and identification of a nematode gene.

Country Status (4)

Country Link
US (2) US7399900B2 (fr)
EP (2) EP1268535B1 (fr)
AU (1) AU2001260140A1 (fr)
WO (1) WO2001070944A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20040198682A1 (en) * 2001-11-30 2004-10-07 Mcswiggen James RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US20050203040A1 (en) * 2001-05-18 2005-09-15 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20040019001A1 (en) * 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US20050196765A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US20050159381A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050176025A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050158735A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US20050143333A1 (en) * 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050233997A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20050288242A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US20050182007A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
GB2382579B (en) * 2001-11-30 2003-11-12 Daniolabs Ltd Disease models, assays, methods and means
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
FR2845245A1 (fr) * 2002-10-07 2004-04-09 Aventis Pharma Sa Modele animal de la maladie de parkinson
AU2005212433B2 (en) 2003-05-23 2010-12-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sINA)
WO2005105157A2 (fr) 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Ofnew York Inhibition d'un arnm associe a une proteine du gene hairless (sans poil)
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
WO2007039454A1 (fr) 2005-09-20 2007-04-12 Basf Plant Science Gmbh Methodes de regulation de l'expression genique utilisant ta-siarn
CA2681323A1 (fr) 2007-03-21 2008-09-25 Brookhaven Science Associates, Llc Compositions combinees de boucle en epingle a cheveux - antisens et procedes pour moduler l'expression
US20100280097A1 (en) * 2007-09-18 2010-11-04 Intradigm Corporation Compositions comprising hif-1 alpha sirna and methods of use thereof
US20100286241A1 (en) * 2007-09-18 2010-11-11 Intradigm Corporation Compositions comprising k-ras sirna and methods of use
WO2011073326A2 (fr) 2009-12-18 2011-06-23 Novartis Ag Compositions organiques de traitement des pathologies liées à hsf1
KR20120125357A (ko) 2010-02-10 2012-11-14 노파르티스 아게 근육 성장을 위한 방법 및 화합물
EP3766975A1 (fr) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
US20130024954A1 (en) * 2011-06-24 2013-01-24 Jonathan Thomas Pierce-Shimomura Human Age-Related Neurodegenerative Nematode Model and Methods
US10023862B2 (en) 2012-01-09 2018-07-17 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat beta-catenin-related diseases
EP3806631A4 (fr) * 2018-06-12 2022-03-30 Rady Children's Hospital Research Center Méthode de dosage de variantes génétiques
CA3131145A1 (fr) * 2019-02-21 2020-08-27 Nemametrix Inc Organismes modeles de maladie monogenique ou polygenique humanises a l'aide de deux genes ou plus
CN114585752A (zh) * 2019-09-12 2022-06-03 奇迹生物公司 用于表征微生物组的组合物和方法
CN114755366A (zh) * 2022-03-28 2022-07-15 上海大学 利用秀丽隐杆线虫综合分析化学品运动神经毒性的方法
CN116509870A (zh) * 2023-03-29 2023-08-01 大连理工大学 油菜花粉碱a在神经保护和脑疾病防治方面的新用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196333A (en) * 1990-05-30 1993-03-23 The Trustees Of Columbia University DNA sequences involved in neuronal degeneration, multicellular organisms containing same and uses thereof
US5962301A (en) 1992-06-12 1999-10-05 Massachusetts Institute Of Technology Relatedness of human interleukin-1β convertase gene to a C. elegans cell death gene, inhibitory portions of these genes and uses therefor
US6329566B1 (en) * 1997-05-29 2001-12-11 The General Hospital Corporation Methods for the detection, treatment, and prevention of neurodegeneration
WO1998059050A1 (fr) * 1997-06-25 1998-12-30 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Clonage d'une mutation genique permettant de deceler la maladie de parkinson
GB9719879D0 (en) * 1997-09-19 1997-11-19 Neuropa Ltd Protein
ATE315645T1 (de) 1998-02-09 2006-02-15 Boehringer Ingelheim Int Dns oder gene, die an der parkinsonschen krankheit beteiligt sind
PL351432A1 (en) * 1999-04-15 2003-04-22 Devgen Nv Compound screening method

Also Published As

Publication number Publication date
EP2319864A3 (fr) 2012-11-21
EP2319864A2 (fr) 2011-05-11
WO2001070944A2 (fr) 2001-09-27
EP1268535A2 (fr) 2003-01-02
US20030177507A1 (en) 2003-09-18
US8193408B2 (en) 2012-06-05
US7399900B2 (en) 2008-07-15
US20080254475A1 (en) 2008-10-16
EP1268535B1 (fr) 2013-05-22
WO2001070944A3 (fr) 2002-03-14

Similar Documents

Publication Publication Date Title
AU2001260140A1 (en) Nematodes as model organisms for the investigation of neurodegenerative diseases, in particular parkinsons disease, uses and methods for the discovery of substances and genes which can be used in the treatment of the above disease states and identification of a nematode gene.
AU2002216273A1 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
AU2001244609A1 (en) Novel protein, dna thereof and process for producing the same
AU2002330215A1 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
AU2001228881A1 (en) Process for extracting astaxanthin pigment from blue-green algae and extracted pigment thereof
AU5680701A (en) Process for extracting astaxanthin pigment from yeast and extracted pigment thereof
AU2002214542A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2001270478A1 (en) Gene expression in biological conditions
AU2002239256A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
AU2002213450A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
AU2002215386A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2001265213A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2003240042A1 (en) A process for the biological treatment of ammonium-rich aqueous media
AU2001249929A1 (en) Fdrg proteins and nucleic acid molecules and uses therefor
AU2001288363A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2001286687A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2001290872A1 (en) Isolated human kinase proteins, nucleic acid molecules and uses thereof
AU2001272910A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2003298570A1 (en) Isolated human hepsin/46 proteins, nucleic acid molecules encoding human hepsin/46 proteins, and uses thereof
AU2002229060A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2001092524A3 (fr) Gene du type myosine exprime dans le coeur et les muscles humains
WO2005049790A3 (fr) Genes et proteines skn-1 et gsk-3
AU2003275946A1 (en) Gene expression in biological conditions
AU2002361950A1 (en) Genes coding for dna replication proteins and for proteins related to pathogenesis
AU2002350599A1 (en) Homeotic genes and proteins, and uses thereof